Evidence map›Paper›PMID 22797877›Full record

ArticleInternational journal of hematology2012

Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells.

Tomasz Kruzel, Maria Sadus-Wojciechowska, Jacek Najda, Tomasz Czerw, Magdalena Glowala-Kosinska, Jerzy Holowiecki, Sebastian Giebel

2 registry-linked trialsAbstract readLetter
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01908621 phase3completednot on this mapstarted 2013, after this paper: background citation

Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Multiple Myeloma Patients.

TypeinterventionalSponsorMaria Sklodowska-Curie National Research Institute of OncologyRan2013 to 2017Enrolled90ConditionsMultiple MyelomaArmsG-CSF (filgrastim), Cytosine arabinoside + G-CSF (filgrastim)
NCT02722733 phase3unknown statusnot on this mapstarted 2016, after this paper: background citation

Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.

TypeinterventionalSponsorMaria Sklodowska-Curie National Research Institute of OncologyRan2016 to 2017Enrolled90ConditionsHodgkin's Lymphoma, Non-Hodgkin's LymphomaArmsG-CSF (filgrastim), Cytosine arabinoside with G-CSF (filgrastim)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomasz Kruzel
Maria Sadus-Wojciechowska
Jacek Najda
Tomasz Czerw
Magdalena Glowala-Kosinska
Jerzy Holowiecki
Sebastian Giebel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell MobilizationAdultAgedCytarabineFemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem CellsHumansMaleMiddle AgedCytarabineGranulocyte Colony-Stimulating Factor

Identifiers

PMID22797877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.